Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;107:1509-1513
Published online before print February 24, 2003, doi: 10.1161/01.CIR.0000056104.49686.4B
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
107/11/1509    most recent
01.CIR.0000056104.49686.4Bv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilkens, H.
Right arrow Articles by Sybrecht, G.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilkens, H.
Right arrow Articles by Sybrecht, G.W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Pulmonary Hypertension
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Pulmonary biology and circulation
Right arrow Pulmonary circulation and disease
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2003;107:1509.)
© 2003 American Heart Association, Inc.


Clinical Investigation and Reports

Influence of Inhaled Iloprost on Transpulmonary Gradient of Big Endothelin in Patients With Pulmonary Hypertension

H. Wilkens, MD; M. Bauer, MD; N. Forestier; J. König, MD; A. Eichler, MD; S. Schneider; H.J. Schäfers, MD; G.W. Sybrecht, MD

From Medizinische Klinik und Poliklinik, Innere Medizin V (H.W., N.F., A.E., G.W.S.), Klinik für Anästhesiologie und Intensivmedizin (M.B., S.S.); Abteilung Thorax- und Herz-Gefäßchirurgie (H.J.S.); and the Institut für Medizinische Biometrie (J.K.), Epidemiologie und Medizinische Informatik, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.

Correspondence to Dr H. Wilkens, Medizinische Klinik und Poliklinik, Innere Medizin V, Universitätskliniken des Saarlandes, D-66421 Homburg/Saar. E-mail inhwil{at}med-rz.uni-saarland.de

Background— The pulmonary circulation is an important site for the production and clearance of endothelin (ET)-1, a potent vasoactive and mitogenic peptide. In healthy individuals, 40% to 50% of circulating ET-1 is removed on each passage through the lungs resulting in an arteriovenous ratio of <1, whereas many patients with pulmonary arterial hypertension (PAH) have ratios >1, indicating reduced clearance or increased release of endothelin. The influence of inhaled prostanoids on endothelin clearance is unknown.

Methods and Results— In a prospective investigation, plasma concentrations of big endothelin-1 (big ET-1, Elisa) were measured in 15 patients with pulmonary hypertension undergoing right heart catheterization with iloprost inhalation (4 m, 11 f, aged 35 to 75 years, mean pulmonary arterial pressure (PAPm) 54±2.3 mm Hg, pulmonary vascular resistance (PVR) 1061±141 dyn x sec x cm-5). There was a significant transpulmonary gradient for big ET-1 with 31% ±11% higher concentrations in the radial artery than in the pulmonary artery (P<0.001). After inhalation of iloprost a significant decrease in the AV-ratio from 1.31±0.11 to 0.92±0.06 (P<0.007) was observed. The pulmonary net release of 3.10±0.65 pmol/min big ET-1 at baseline decreased to -1.24±1.32 pmol/min (P=0.013) within 15 minutes indicating a restored balance. Patients under long-term treatment with iloprost (n=7) tended to have a lower net release and AV-ratio for big ET-1 than patients without pretreatment.

Conclusion— An increase in pulmonary clearance of big-ET could be a mechanism contributing to the beneficial effects of inhaled prostanoids in the treatment of PAH.


Key Words: hypertension, pulmonary • endothelin • prostaglandins




This article has been cited by other articles:


Home page
Eur Respir JHome page
G. Warwick, P. S. Thomas, and D. H. Yates
Biomarkers in pulmonary hypertension
Eur. Respir. J., August 1, 2008; 32(2): 503 - 512.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
T. Kramm, B. Eberle, S. Guth, and E. Mayer
Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy
Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 882 - 888.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
S. E Baker and R. H. Hockman
Inhaled Iloprost in Pulmonary Arterial Hypertension
Ann. Pharmacother., July 1, 2005; 39(7): 1265 - 1274.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A. Peacock, R. Naeije, N. Galie, and J.T. Reeves
End points in pulmonary arterial hypertension: the way forward
Eur. Respir. J., June 1, 2004; 23(6): 947 - 953.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Galie, A. Manes, and A. Branzi
The endothelin system in pulmonary arterial hypertension
Cardiovasc Res, February 1, 2004; 61(2): 227 - 237.
[Abstract] [Full Text] [PDF]